Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations.
Ibrutinib induces durable remissions in treatment-na?ve patients with CLL and 17p deletion and/or TP53 mutations. Blood. 2021 12 16; 138(24):2589-2592.